中图分类号:
马丁. 上皮性卵巢癌组织起源与肿瘤发生新进展--“二元论”学说[J]. 中国实用妇科与产科杂志.
[1] Ovarian cancer, five-year stage-specific relative survival rates (2004-2008). Journal of the National Cancer Institute, 2011,103:1287.[2] Powell DE, Puls L, van Nagell J. Current concepts in epithelial ovarian tumors: does benign to malignant transformation occur?[J]. Human Pathology, 1992,23:846-847.[3] Puls LE, Powell DE, DePriest PD,et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma[J]. Gynecol Oncol,1992,47:53-57.[4] Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes?[J]. Gynecol Oncol, 1999,72:437-442.[5] Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma[J]. The American Journal of Pathology, 2002,160:1223-1228.[6] Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis[J]. The American Journal of Pathology, 2004,164:1511-1518.[7] Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system[J]. The American Journal of Surgical Pathology, 2004,28:496-504.[8] Cho KR, Shih IM. Ovarian cancer[J]. Annual Review of Pathology, 2009,4:287-313.[9] Kurman RJ, Shih IM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. International journal of gynecological pathology : official journal of the international[J]. Society of Gynecological Pathologists, 2008,27:151-160.[10] Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma[J]. Nature, 2011,474:609-615.[11] Kindelberger DW, Lee Y, Miron A,et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship[J]. The American Journal of Surgical Pathology, 2007,31:161-169.[12] Lee Y, Miron A, Drapkin R,et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube[J]. The Journal of Pathology, 2007,211:26-35.[13] Pothuri B, Leitao MM, Levine DA, et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma[J]. PloS One, 2010,5:e10358.[14] Dehari R, Kurman RJ, Logani S,et al. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis[J]. The American Journal of Surgical Pathology, 2007,31:1007-1012.[15] Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems[J]. Advances in Anatomic Pathology, 2009,16:267-282.[16] May T, Virtanen C, Sharma M,et al. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary[J]. Gynecol Oncol,2010,117:9-17.[17] Seidman JD, Kurman RJ. Treatment of micropapillary serous ovarian carcinoma (the aggressive variant of serous borderline tumors)[J]. Cancer, 2002,95:675-676.[18] Li J, Abushahin N, Pang S,et al. Tubal origin of 'ovarian' low-grade serous carcinoma[M]. Modern Pathology:An Official journal of the United States and Canadian Academy of Pathology,2011:1488-1499.[19] Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial[J]. Obstet Gynecol, 2009,113:775-782.[20] Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial[J]. Am J of Obstetrics and Gynecology, 2005,193:1630-1639.[21] Santillan A, Kim YW, Zahurak ML,et al. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma: international journal of gynecological cancer : official journal of the international[J]. Gynecological Cancer Society, 2007,17:601-606. |
[1] | 刘兴会, 马宏伟, 张 彦. 控制剖宫产率从减少阴道分娩并发症做起[J]. 中国实用妇科与产科杂志, 2022, 38(8): 769-772. |
[2] | 吕卫国, 陈丽莉. 重视妊娠滋养细胞肿瘤的规范化治疗[J]. 中国实用妇科与产科杂志, 2022, 38(7): 673-675. |
[3] | 陶 祥, 陈婷婷, 周先荣. 妊娠滋养细胞疾病的组织病理学和分子病理学研究现状[J]. 中国实用妇科与产科杂志, 2022, 38(7): 676-680. |
[4] | 彭美莲, 林开武, 翁宗杰, 吴齐斌, 孙蓬明. 妊娠滋养细胞疾病的影像学特征及意义[J]. 中国实用妇科与产科杂志, 2022, 38(7): 680-684. |
[5] | 程广艳, 曲芃芃. 葡萄胎的规范化处理[J]. 中国实用妇科与产科杂志, 2022, 38(7): 684-687. |
[6] | 刘晓梅, 李秀琴. 低危妊娠滋养细胞肿瘤的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(7): 687-691. |
[7] | 李克敏, 尹如铁. 高危妊娠滋养细胞肿瘤的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(7): 691-693. |
[8] | 程红燕, 向 阳. 妊娠滋养细胞肿瘤的免疫治疗[J]. 中国实用妇科与产科杂志, 2022, 38(7): 693-696. |
[9] | 王芬芬, 鲍可纯, 程晓东. 特殊病理类型妊娠滋养细胞肿瘤的治疗[J]. 中国实用妇科与产科杂志, 2022, 38(7): 696-701. |
[10] | 奚 玲, 孙 玥. 妊娠滋养细胞肿瘤生育力保留策略[J]. 中国实用妇科与产科杂志, 2022, 38(7): 701-704. |
[11] | 中国优生科学协会肿瘤生殖学分会 中国医师协会微无创医学专业委员会妇科肿瘤学组 中国医院协会妇产医院分会妇科肿瘤专业学组. 卵巢恶性肿瘤保留生育功能的中国专家共识(2022年版)[J]. 中国实用妇科与产科杂志, 2022, 38(7): 705-713. |
[12] | 程傲霜, 林仲秋. 女性恶性肿瘤患者生育力的保护与保存[J]. 中国实用妇科与产科杂志, 2022, 38(6): 604-609. |
[13] | 黄晨阳, 孙海翔. 妇科恶性肿瘤患者促排卵及胚胎移植方案的选择[J]. 中国实用妇科与产科杂志, 2022, 38(6): 614-618. |
[14] | 中国医师协会妇产科医师分会人工智能专业组. 子宫颈癌手术治疗质量控制标准中国专家共识之QM-A型/QM-B1型广泛性子宫切除篇[J]. 中国实用妇科与产科杂志, 2022, 38(6): 628-633. |
[15] | 中国抗癌协会妇科肿瘤专业委员会. 早期子宫颈癌保留生育功能中国专家共识[J]. 中国实用妇科与产科杂志, 2022, 38(6): 634-641. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||